The average animal

Why this result

Keystone Peptide is an editorial site about published Epitalon research. It grew from an argument with a mouse experiment that reported increased maximum lifespan alongside an unchanged mean. I wanted the average animal to remain visible in a story so easily organised around an exceptional survivor.

Keystone names the supporting result in a larger argument. If a claim concerns extending life generally, I judge that claim partly by how much of its weight the group’s survival can bear. I favour an improvement that reaches across the animals. The furthest survivors still pose a biological puzzle I would enjoy seeing solved.

That preference is open to argument. A repeat that explained the whole survival distribution and accounted carefully for harms could change the place of the maximum in my argument. Such a disagreement would be welcome.

Telomeres and human survival

The normal- and breast-cancer cell work complicates an easy enthusiasm for telomere lengthening. The human mortality follow-up complicates the habit of gathering related preparation names under a single longevity claim. Those findings supply the friction that makes this subject worth a closer look.

Declaring this line of research either a triumph or a dead end would satisfy neither my curiosity nor my scepticism. The mouse paper alone contains enough mixed outcomes to reward a more patient argument. Its exceptional survivors deserve an explanation, and its unchanged mean deserves equal space.

I return to a narrow question: what exactly improved, for whom, and how widely? I would prize a well-bounded answer over an expansive claim about rejuvenation.

Medical decisions

These essays concern experiments and the conclusions I think they support. They offer no medical advice or treatment plan. Keystone Peptide has no clinical or retail operation; there is nothing to arrange or obtain here. Personal decisions about health belong in a conversation with a qualified clinician who can consider the person involved.